Global Blood Therapeutics Market Cap
Global Blood Therapeutics Inc a biopharmaceutical company engages in the discovery development and delivery of treatments for underserved patient communities. Market cap market capitalization is the total market value of a publicly traded companys outstanding shares.
Global Blood Therapeutics Gbt Market Capitalization
You are now leaving the Global Blood Therapeutics website You are currently leaving our site.
Global blood therapeutics market cap. Global Blood Therapeutics Inc. Global Blood Therapeutics NASDAQGBT last released its quarterly earnings data on Tuesday May 4th. In depth view into Global Blood Therapeutics Market Cap including historical data from 2015 charts stats and industry comps.
About Market Cap Global Blood Therapeutics has a market cap of 263 B which represents its current share price of 4260 multiplied by its outstanding share number of 618. Market capitalization of Global Blood Therapeutics GBT Market cap. GBT stock price news historical charts analyst ratings and financial information from WSJ.
External links are being provided as a convenience and for informational purposes only. How many employees does Global Blood Therapeutics have. Global Blood Therapeutics started at buy with 112 stock price target at Stifel Nicolaus Apr.
Global Blood Therapeutics has a market capitalization of 220 billion and generates 211 million in revenue each year. As a mid-cap company. On 31 December 2020 the US25b.
Market capitalization or market value is the most commonly used method of measuring the size of a publicly traded company and is calculated by multiplying the current stock price by the number of shares outstanding. It also provides oral medicines for sickle cell diseases. GBT Global Blood Therapeutics s market cap is 265B as of Mar 13 2021.
Is a clinical-stage biopharmaceutical company which engages in the discovering developing and commercializing novel therapeutics to treat grievous blood-based disorders. Global Blood Therapeutics NASDAQGBT last released its quarterly earnings results on Tuesday February 23rd. Global Blood Therapeutics Inc.
This makes Global Blood Therapeutics the worlds 3103th most valuable company by market cap according to our data. Global Blood Therapeutics market cap history and chart from 2014 to 2021. Is a clinical-stage biopharmaceutical company which engages in the discovering developing and commercializing novel therapeutics to treat grievous blood-based disorders.
The company earns -26677000000 in net income profit each year or 471 on an earnings per share basis. Global Blood Therapeutics has a one year low of 3649 and a one year high of 8369. It also provides oral medicines for sickle cell diseases.
The company reported 121 EPS for the quarter missing the consensus estimate of 101 by 020. They do not constitute an endorsement or an approval by Global Blood Therapeutics. 28 2020 at 756 am.
Global Blood Therapeutics market cap as of May 07 2021 is 24B. ET by Tomi Kilgore Global Blood Therapeutics stock price target cut to 75 from. Global Blood Therapeutics had a negative return on equity of 5643 and a negative net margin of 33294.
As of May 2021 Global Blood Therapeutics has a market cap of 240 B. The stock that epitomizes the said phenomenon is Global Blood Therapeutics Subsequent to launching Oxbryta GBT shares rallied to a peak of 8376 in early 2020. View the latest Global Blood Therapeutics Inc.
The market capitalization commonly called market cap is the total market value of a publicly traded companys outstanding. The company reported 100 earnings per share EPS for the quarter missing the Thomson Reuters consensus estimate of 097 by 003. The decline came after the company announced its first-quarter results following the market.
View GBT Global Blood Therapeutics stock share price financial statements key ratios and more at Craft. Shares of Global Blood Therapeutics NASDAQGBT were sinking 8 as of 1114 am. GBT Global Blood Therapeutics market cap is 28 b and annual revenue was 211 m in FY 2019.
Thereafter the stock has been.
Gbt Stock Must Maintain Current Level Of Price Support
Global Blood Therapeutics Stock Nasdaq Gbt Breaks Out Here Are The Implications
Global Blood Therapeutics Oxbryta Is Aimed For Success Nasdaq Gbt Seeking Alpha
Global Blood Therapeutics A Promising Biotech Pick In 2019 Nasdaq Gbt Seeking Alpha
Global Blood Therapeutics Investment Risk Diminishing As Oxbryta Outperforms Nasdaq Gbt Seeking Alpha
Global Blood Therapeutics Nothing Exciting Yet Nasdaq Gbt Seeking Alpha
Global Blood Therapeutics Oxbryta Is Aimed For Success Nasdaq Gbt Seeking Alpha
Global Blood Therapeutics Gbt Investor Presentation Slideshow Nasdaq Gbt Seeking Alpha
Technical Analysis Global Blood Therapeutics Stock Nasdaq Gbt Chart Is A Must See
Global Blood Therapeutics Investment Risk Diminishing As Oxbryta Outperforms Nasdaq Gbt Seeking Alpha
Global Blood Therapeutics Gbt Investor Presentation Slideshow Nasdaq Gbt Seeking Alpha
Gbt Global Blood Therapeutics Stock Price
Bn7a 9ogw7u0fm
Global Blood Therapeutics Stock Sell Off Alters My Investment Strategy Gbt Seeking Alpha
Global Blood Therapeutics Nasdaq Gbt Price Target Cut To 110 00 By Analysts At Cantor Fitzgerald Marketbeat
Global Blood Therapeutics Gbt Investor Presentation Slideshow Nasdaq Gbt Seeking Alpha
I K9r1a Fpxfdm
Post a Comment for "Global Blood Therapeutics Market Cap"